Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
October 28, 2015 7:05 AM EDT
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $342.00 (from $311.00), following a 60 person MEDACorp survey of US plastic surgeons and dermatologists. Specialists in the survey were bullish on Kybella and expect the drug to increase their submental fat patient... More
October 27, 2015 6:12 AM EDT
Allergan (NYSE: AGN) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced that Allergan has acquired rights to CONSTELLA (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS® (linaclotide) in Mexico from Almirall.
Under the terms of the agreement, Allergan acquired an exclusive license for CONSTELLA in these countries. The license agreement includes the development and commercialization of CONSTELLA for the treatment of irritable bowel syndrome with... More
